These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 109501)

  • 41. Effects of dietary glutamine on antioxidant enzyme activity and immune response in burned mice.
    Yeh SL; Shang HF; Lin MT; Yeh CL; Chen WJ
    Nutrition; 2003 Oct; 19(10):880-5. PubMed ID: 14559325
    [TBL] [Abstract][Full Text] [Related]  

  • 42. PcrV immunization enhances survival of burned Pseudomonas aeruginosa-infected mice.
    Holder IA; Neely AN; Frank DW
    Infect Immun; 2001 Sep; 69(9):5908-10. PubMed ID: 11500471
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pseudomonas aeruginosa polysaccharide-tetanus toxoid conjugate vaccine: safety and immunogenicity in humans.
    Cryz SJ; Sadoff JC; Fürer E; Germanier R
    J Infect Dis; 1986 Oct; 154(4):682-8. PubMed ID: 3091708
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Motility, virulence, and protection with a flagella vaccine against Pseudomonas aeruginosa infection.
    Montie TC; Drake D; Sellin H; Slater O; Edmonds S
    Antibiot Chemother (1971); 1987; 39():233-48. PubMed ID: 3118785
    [No Abstract]   [Full Text] [Related]  

  • 45. [Ps. aeruginosa lipopolysaccharide vaccine in the treatment of burns (report of 30 cases)].
    Yu HX
    Zhonghua Zheng Xing Shao Shang Wai Ke Za Zhi; 1988 Mar; 4(1):38-40. PubMed ID: 3151316
    [No Abstract]   [Full Text] [Related]  

  • 46. [Course of immunoglobulins G and M in seriously burned patients].
    Zellner PR; Schlayer G; Möller I; Köhler G
    Chirurg; 1977 Aug; 48(8):516-9. PubMed ID: 902533
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A new polyvalent pseudomonas vaccine.
    Merle P; Robbel L; Hungerer KD
    Behring Inst Mitt; 1984 Nov; (76):113-20. PubMed ID: 6441560
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Development of immunotherapy for infections due to Pseudomonas aeruginosa.
    Fisher MW
    J Infect Dis; 1974 Nov; 130 Suppl(0):S149-51. PubMed ID: 4138585
    [No Abstract]   [Full Text] [Related]  

  • 49. Outer membrane protein F preparation of Pseudomonas aeruginosa as a vaccine against chronic pulmonary infection with heterologous immunotype strains in a rat model.
    Gilleland HE; Gilleland LB; Matthews-Greer JM
    Infect Immun; 1988 May; 56(5):1017-22. PubMed ID: 2833440
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A multicenter vaccine trial using the Pseudomonas aeruginosa flagella vaccine IMMUNO in patients with cystic fibrosis.
    Döring G; Dorner F
    Behring Inst Mitt; 1997 Feb; (98):338-44. PubMed ID: 9382758
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Active immunization of burned patients with a new multivalent Staphylococcus-Pseudomonas vaccine.
    Sachs A
    Prog Immunobiol Stand; 1971; 5():428-32. PubMed ID: 4633971
    [No Abstract]   [Full Text] [Related]  

  • 52. [Immunomodulation in Pseudomonas urinary infection].
    Urban M; Tamele L
    Rozhl Chir; 1995 Nov; 74(7):319-21. PubMed ID: 8629153
    [TBL] [Abstract][Full Text] [Related]  

  • 53. X-ray Irradiated Vaccine Confers protection against Pneumonia caused by Pseudomonas aeruginosa.
    Li Y; Wang Z; Liu X; Tang J; Peng B; Wei Y
    Sci Rep; 2016 Feb; 6():18823. PubMed ID: 26879055
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical study to assess the immunogenicity and safety of a recombinant Pseudomonas aeruginosa OprF-OprI vaccine in burn patients.
    Mansouri E; Blome-Eberwein S; Gabelsberger J; Germann G; von Specht BU
    FEMS Immunol Med Microbiol; 2003 Jul; 37(2-3):161-6. PubMed ID: 12832120
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Assessment of the effectiveness of antipseudomonas biological management in the control of infection in burn patients.
    Gonzáles Ayala SE; Daroda M; Villa J; Cecchini E; Vich J
    Panminerva Med; 1983; 25(3):203-8. PubMed ID: 6422426
    [No Abstract]   [Full Text] [Related]  

  • 56. Effects of somatic component of Pseudomonas aeruginosa on protective immunity in experimental mouse burn infection.
    Okada K; Kawaharajo K; Kasai T; Homma JY
    Jpn J Exp Med; 1980 Feb; 50(1):53-61. PubMed ID: 6770131
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Pseudomonas immunoglobulin prophylaxis in patients with burn injuries].
    Stuttmann R; Petrovici V; Hartert M
    Infection; 1987; 15 Suppl 2():S71-5. PubMed ID: 3112025
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A polyvalent Pseudomonas vaccine.
    Sato H; Diena BB
    Rev Can Biol; 1974 Jun; 33(2):93-7. PubMed ID: 4211759
    [No Abstract]   [Full Text] [Related]  

  • 59. Affinity constants of naturally acquired and vaccine-induced anti-Pseudomonas aeruginosa antibodies in healthy adults and cystic fibrosis patients.
    Bruderer U; Cryz SJ; Schaad UB; Deusinger M; Que JU; Lang AB
    J Infect Dis; 1992 Aug; 166(2):344-9. PubMed ID: 1634805
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Testing the protective effectiveness of vaccines against infection with Pseudomonas aeruginosa in mink (Lutreola vison)].
    Dousek J; Sourek J; Dvorák R; Hartman V; Vejlupek O
    Vet Med (Praha); 1986 Nov; 31(11):695-704. PubMed ID: 3097914
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.